News | Stents Peripheral | March 16, 2017

Gore Tigris Vascular Stent Gains Health Canada Approval for Treatment of Peripheral Artery Disease

Novel device combines proven technology with modern adaptations to provide support in even the most challenging anatomies

Gore Tigris Vascular Stent, Health Canada approval, PAD, peripheral artery disease

March 16, 2017 — W. L. Gore & Associates Inc. recently announced the Health Canada approval of the Gore Tigris Vascular Stent, a dual-component stent with a fluoropolymer/nitinol design. The device, which gained CE Mark approval in 2011, is a third-generation, self-expanding stent that was designed explicitly to improve anatomical conformability with the natural movement of the knee when treating peripheral artery disease (PAD).

The newly-approved Gore Tigris uses a dual component structure, made from a single-wire nitinol stent with flexible and biocompatible fluoropolymer interconnections. The stent has been designed to weather biomechanical forces (extension, compression, flexion and torsion) without fractures, even in the most complex anatomies, namely in the superficial femoral artery (SFA) and popliteal arteries. In the U.S. clinical study that supported U.S. Food and Drug Administration (FDA) approval, the stent was found to have zero fractures at 12 months, while the control arm devices experienced a 27 percent fracture rate at the same time point.

The Gore Tigris also features the company’s CBAS Heparin Surface, a heparin bonding technology designed to resist thrombus formation, a problem common in both bare metal and drug-eluting stents. End-point covalent bonding keeps heparin anchored to the stent surface, while the bioactive site remains free to interact with the blood to help prevent clotting.

The evolution of peripheral stenting over the past decade has allowed for broader adoption of endovascular therapy for treating PAD. When physicians began placing stents in the SFA, they were limited by first-generation stent designs that had longitudinal metal connections that led to arterial stiffening, high fracture rates and poorer clinical outcomes. Improvements in second-generation devices introduced helical interconnections to improve flexibility; however, their success in high flexion vessels, like the distal SFA and proximal popliteal artery, was still limited. The introduction of third-generation stents, including the Gore Tigris, allow for better adherence in some of the more intricate vessels in the body.

PAD is prevalent in older populations, a rapidly growing demographic in developed countries. In Canada alone, as many as 800,000 people suffer from some form of PAD. The disease can manifest in mild symptoms such as chronic leg pain, and more serious complications include poor wound healing, increased risk of stroke, and amputation. Endovascular treatment, via angioplasty and stenting of a blocked artery, is designed to treat PAD without the complications that can accompany open surgery.

For more information: www.goremedical.com

Related Content

News | Cath Lab

May 31, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, announced that the company has received ...

Home May 31, 2022
Home
News | Cath Lab

May 26, 2022 — The U.S. Food and Drug Administration (FDA) has recalled the Dragonfly OpStar Imaging Catheter, and has ...

Home May 26, 2022
Home
News | Cath Lab
April 25, 2022 – NewYork-Presbyterian Hudson Valley Hospital celebrated the launch of its interventional cardiology ...
Home April 25, 2022
Home
News | Cath Lab
April 18, 2022 – Royal Philips and Oulu University Hospital (Finland) have announced a strategic 10-year partnership ...
Home April 18, 2022
Home
News | Cath Lab
February 16, 2022 – Fremont Bank Foundation recently donated $750,000 to its community partner, St. Rose Hospital ...
Home February 16, 2022
Home
News | Cath Lab
February 14, 2022 — A collaborative effort between The Valley Heart and Vascular Institute’s cardiology team ...
Home February 14, 2022
Home
Sponsored Content | Videos | Cath Lab

Advancements in analytics and data visualizations are helping to streamline operations and improve productivity at cath ...

Home January 13, 2022
Home
News | Cath Lab

January 4, 2022 — The U.S. Food and Drug Administration (FDA) has authorized marketing of the first laser-based device ...

Home January 04, 2022
Home
News | Cath Lab

December 14, 2021 — RSIP Vision, a medical imaging company applying advanced artificial intelligence (AI) and computer ...

Home December 14, 2021
Home
Feature | Cath Lab

November 15, 2021 — RealView Imaging Ltd. recently received FDA 510(k) clearance for its Holoscope-i holographic system ...

Home November 15, 2021
Home
Subscribe Now